The applications of animal models in phage therapy : An update
The rapid increase in antibiotic resistance presents a dire situation necessitating the need for alternative therapeutic agents. Among the current alternative therapies, phage therapy (PT) is promising. This review extensively summarizes preclinical PT approaches in various in-vivo models. PT has been evaluated in several recent clinical trials. However, there are still several unanswered concerns due to a lack of appropriate regulation and pharmacokinetic data regarding the application of phages in human therapeutic procedures. In this review, we also presented the current state of PT and considered how animal models can be used to adapt these therapies for humans. The development of realistic solutions to circumvent these constraints is critical for advancing this technology.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:19 |
|---|---|
| Enthalten in: |
Human vaccines & immunotherapeutics - 19(2023), 1 vom: 31. Dez., Seite 2175519 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mehmood Khan, Fazal [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Animal infection model |
|---|
| Anmerkungen: |
Date Completed 31.03.2023 Date Revised 28.04.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/21645515.2023.2175519 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM354407422 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM354407422 | ||
| 003 | DE-627 | ||
| 005 | 20231226210121.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/21645515.2023.2175519 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1181.xml |
| 035 | |a (DE-627)NLM354407422 | ||
| 035 | |a (NLM)36935353 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mehmood Khan, Fazal |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The applications of animal models in phage therapy |b An update |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 31.03.2023 | ||
| 500 | |a Date Revised 28.04.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The rapid increase in antibiotic resistance presents a dire situation necessitating the need for alternative therapeutic agents. Among the current alternative therapies, phage therapy (PT) is promising. This review extensively summarizes preclinical PT approaches in various in-vivo models. PT has been evaluated in several recent clinical trials. However, there are still several unanswered concerns due to a lack of appropriate regulation and pharmacokinetic data regarding the application of phages in human therapeutic procedures. In this review, we also presented the current state of PT and considered how animal models can be used to adapt these therapies for humans. The development of realistic solutions to circumvent these constraints is critical for advancing this technology | ||
| 650 | 4 | |a Review | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a ESKAPE Pathogens | |
| 650 | 4 | |a Endolysin | |
| 650 | 4 | |a Phage therapy | |
| 650 | 4 | |a animal infection model | |
| 650 | 4 | |a antimicrobial resistance | |
| 650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
| 700 | 1 | |a Manohar, Prasanth |e verfasserin |4 aut | |
| 700 | 1 | |a Singh Gondil, Vijay |e verfasserin |4 aut | |
| 700 | 1 | |a Mehra, Nancy |e verfasserin |4 aut | |
| 700 | 1 | |a Kayode Oyejobi, Greater |e verfasserin |4 aut | |
| 700 | 1 | |a Odiwuor, Nelson |e verfasserin |4 aut | |
| 700 | 1 | |a Ahmad, Tauseef |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Guangtao |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Human vaccines & immunotherapeutics |d 2012 |g 19(2023), 1 vom: 31. Dez., Seite 2175519 |w (DE-627)NLM21576823X |x 2164-554X |7 nnns |
| 773 | 1 | 8 | |g volume:19 |g year:2023 |g number:1 |g day:31 |g month:12 |g pages:2175519 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/21645515.2023.2175519 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 19 |j 2023 |e 1 |b 31 |c 12 |h 2175519 | ||